Fisetin-derived senolytics SR29384 and SR31133 in aged mice: an abstract
In an abstract, two new fisetin-derived compounds, SR29384 and SR31133, showed stronger senolytic activity than fisetin in mouse models of aging and improved healthspan-associated measures; this is preclinical work, not evidence of human benefit. [1]
Automatic summary · not editorially reviewed
The key findings
Fisetin, a natural flavonoid senolytic, has reached clinical trials but is limited by suboptimal efficacy and poor bioavailability. [1]
SR29384 and SR31133 reduced tissue senescence and improved healthspan-associated parameters in mouse models of aging. [1]
The abstract says the compounds may target PARP1, CDK2 and possibly BCL-xL to selectively induce apoptosis in senescent cells. [1]
The source at a glance
- Study type / format
- Abstract of a preclinical drug discovery study
- Population / context
- Mouse models of aging; senescent cell types in laboratory work
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Why fisetin needed improvement
The abstract states that senescent cells are a key driver of aging and contribute to many age-related diseases. Senolytics are agents that selectively eliminate senescent cells and are described as a promising strategy for age-related diseases, but they face significant barriers to clinical translation. Fisetin, a natural flavonoid senolytic, has reached clinical trials but is limited by suboptimal efficacy and poor bioavailability. The authors therefore set out to develop new fisetin-derived compounds.
Supporting source [1]
Two new compounds in mouse models
Using an integrative phenotypic drug discovery approach, the authors developed SR29384 and SR31133. According to the abstract, these compounds show enhanced senolytic activity, target a broad range of senescent cell types, reduce tissue senescence and improve healthspan-associated parameters in mouse models of aging. The abstract does not report which healthspan measures were used, how many mice were studied, how long they were followed or how the compounds were compared with fisetin.
Supporting source [1]
Proposed molecular targets, not proven causes
Mechanistic work combined transcriptomics, machine learning, network pharmacology and molecular docking. The abstract says the new senolytics may target key molecular pathways, including PARP1, CDK2 and possibly BCL-xL, to selectively induce apoptosis (programmed cell death) in senescent cells. The word may signals a proposed mechanism, not a confirmed one. The authors describe high translational potential, but the abstract reports no human study, so no human lifespan or disease benefit is shown.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. It reports no sample sizes, follow-up, specific healthspan measures, comparator details or human data, so the findings are preclinical and do not establish human benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhang LJ, Salekeen R, Soto-Palma C, Wu Q, He Y, Elsallabi O, Bdiri B, Hughes B, Nunes A, Xu W, Zhang B, Mohamed A, McGowan SJ, Angelini L, O'Kelly R, Kamenecka TM, Niedernhofer LJ, Robbins PD. · europepmc.org · October 1, 2026